ArticleThe oncologist2025
Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer.
Alexis LeVee et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it